University of Liverpool spin-out company receives £400k investment
Sepsis Limited, a spin-out company of the University of Liverpool, has secured a £400k boost to develop a point-of-care tool used in the early detection of sepsis.
The cash, which includes private equity investment as well as funding through a SMART Award, will help the company test a working prototype of a handheld device it hopes will save lives.
Spun out in 2010, Sepsis Limited was founded on the research of Professor Cheng Hock Toh, a blood specialist at the Institute of Infection and Global Health in Liverpool, which saw patented technology developed by the university handed over to the new company.
Sepsis, or blood poisoning, kills around 37k people in the UK every year.
Professor Toh, who also works with the Royal Liverpool University Hospital delivering direct patient care, said: “This is an important step in translating original research from Liverpool into a global test that can improve antibiotic treatment and save lives.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Talent is an asset, not an operational resource
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution